Researchers from Egypt, India, and the UK are studying the role of 3D printing in drug delivery systems. Their findings are detailed in the recently released ‘Pharmaceutical Particulates and Membranes for the Delivery of Drugs and Bioactive Moleclules,’ as they review new trends and developments.
In reviewing twelve different papers on the subject of pharmaceutical particulates and membranes, the researchers also collaborated with experts regarding design, materials, and applications; for instance, in a study by Kumar et al. , the researchers learned of an extended release drug delivery system for nicotine that shows potential for Parkinson’s disease interventions:
“These have been developed in the form of membranes with minimal rates of matrix degradation and retarding nicotine release. This has led to the zero-order release for 50 days following exposure to simulated cerebrospinal fluid (CSF),” stated the researchers.
Mora-Espíet et al.  have explored the targeting of microparticles and culturing breast cancer cell lines. Huang et al.  confirmed a new process for accelerating drug dissolution with ibuprofen-loaded hydroxypropyl methylcellulose nanoparticles.
“During this process, it was shown that a key parameter, i.e., the spreading angle of atomization could provide a linkage among the working process, the property of generated nanoparticles and their functional performance,” stated the researchers. “They confirmed that the nanoparticle diameter (prepared based on a modified technique) has a profound influence on the drug release performance.”
Shah et al.  contributed a study as they moved forward to refine the effectiveness of moxifloxacin, an antibiotic used to treat a variety of bacterial infections. With a new system for optimizing nanoemulsion, they were able to ‘enhance the therapeutic effects of moxifloxacin,’ resulting in safe delivery.
Another development, contributed by Wan et al. , allowed for sustained release of loxoprofen sodium (LXP), with the addition of a unique coating:
“Their results identified both the citric acid (CA) and ADEC as the dissolution and diffusion-rate controlling materials significantly decreasing the drug release rate,” stated the researchers. “The optimal formulation for a pH-independent drug release in media has been suggested as at a pH above 4.5 and at slightly slow release in acid medium.
“The pharmacokinetic studies have revealed that a more stable and prolonged plasma drug concentration profile of the optimal pellets has been achieved, with a relative bioavailability of 87.16% compared with the conventional tablets.”
Studying magnetic nanoparticles, Iglesias et al.  stated that BMNPs (biometic) were superior to MNPs (inorganic) for drug loading of molecules ‘positively charged at neutral pH.’ MNPs, however, have the potential for suitable transport abilities while under a magnetic field. Savin et al  explored gel formulations for skin melanoma treatment, along with fabricating breast cancer cells in 3D models—following one of the major trends in medicine today using models for treatment, training, and surgical planning too.
“The in vitro results for the tested CD-NHF-loaded gel formulations have revealed that the new composites can affect the number, size, and cellular organization of spheroids and impact individual tumor cell ability to proliferate and aggregate in spheroids,” stated the researchers.
Guadarrama-Acevedo et al.  created a new wound dressing made of alginate membrane and polycaprolactone nanoparticles, loaded with curcumin for healing. Integrating nanocarriers allows for drug permeation into multiple layers of skin, thus eliminating solubility issues with curcumin. Rancan et al.  performed research showing that after six hours, nanofiber mats offer the best drug concentration upon delivery.
Further, Lian et al.  developed a system for using red blood cell membrane-camouflaged ATO-loaded sodium alginate nanoparticles (RBCM-SA-ATO-NPs, RSANs) to eliminate toxicity of ATO. Their work also showed that RSANS have lower levels of cytotoxicity, upon comparison with normal cells; RSANS also displayed antitumor effects on NB4 cells and 7721 cells.
Adeleke et al.  developed an isoniazid suspension as an antitubercular agent against TB, offering extended release:
RDS has been dispersible and stable in the dried and reconstituted states over 4 months and 11 days respectively, under common storage conditions.
“The published papers are also being compiled as an edited e-book, to be published by MDPI,” stated the researchers.
What do you think of this news? Let us know your thoughts! Join the discussion of this and other 3D printing topics at 3DPrintBoard.com.[Source / Images: ‘Pharmaceutical Particulates and Membranes for the Delivery of Drugs and Bioactive Moleclules’]
You May Also Like
VELO3D Going Public Will Take Metal Powder Bed Fusion to New Territory
Over the last six months, the additive manufacturing industry has been riding a wave not seen in a decade. In March, the rumors that VELO3D—one of the youngest companies in...
Zmorph Announces Industrial Grade 3D Printer Zmorph i500
Poland’s Zmorph, a manufacturer of multitool 3D printers, has announced its newest model, Zmorph i500, is now entering the industrial market. The Zmorph i500 will be released April 20, 2021....
Nexa3D Introduces Large-Format NXD200 3D Printer for Dental Labs
California-based Nexa3D makes ultrafast, industrial-grade polymer production 3D printers, like its NXE400, and today has announced the newest member of the family: the large-format NXD200 dental lab 3D printer. Just...
3D Printing News Briefs, April 3, 2021: Mirai Foods, Markforged, DyeMansion, Fictiv, Lithoz
With stories ranging from funding for 3D printed meat products and on-demand print finishing services to a new entry-level ceramic 3D printer, we’ve got plenty of news to cover in...
View our broad assortment of in house and third party products.